SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022054
Filing Date
2022-11-04
Accepted
2022-11-04 07:31:07
Documents
70
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20220930.htm   iXBRL 10-Q 3592944
2 EX-31.1 akro-ex31_1.htm EX-31.1 22265
3 EX-31.2 akro-ex31_2.htm EX-31.2 21916
4 EX-32.1 akro-ex32_1.htm EX-32.1 19608
  Complete submission text file 0000950170-22-022054.txt   10993847

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akro-20220930_def.xml EX-101.DEF 176258
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akro-20220930.xsd EX-101.SCH 52314
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akro-20220930_cal.xml EX-101.CAL 41860
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akro-20220930_pre.xml EX-101.PRE 336958
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akro-20220930_lab.xml EX-101.LAB 449838
64 EXTRACTED XBRL INSTANCE DOCUMENT akro-20220930_htm.xml XML 2163871
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 221360191
SIC: 2834 Pharmaceutical Preparations